Shi Y, Zheng M (2020) Hepatitis B virus persistence and reactivation. BMJ 370:m2200. https://doi.org/10.1136/bmj.m2200

Article  PubMed  Google Scholar 

Perrillo RP, Gish R, Falck-Ytter YT (2015) American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148(221–244):e223. https://doi.org/10.1053/j.gastro.2014.10.038

Article  Google Scholar 

Loomba R, Liang TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152:1297–1309. https://doi.org/10.1053/j.gastro.2017.02.009

Article  PubMed  Google Scholar 

Hwang JP, Feld JJ, Hammond SP et al (2020) Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol 38:3698–3715. https://doi.org/10.1200/JCO.20.01757

Article  CAS  PubMed  Google Scholar 

Hwang JP, Somerfield MR, Alston-Johnson DE et al (2015) Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol 33:2212–2220. https://doi.org/10.1200/JCO.2015.61.3745

Article  PubMed  PubMed Central  Google Scholar 

Administration FaD (2013) FDA drug safety communication: boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-boxed-warning-and-new-recommendations-decrease-risk-hepatitis-b.

Lee J, Park JY, Kim DG et al (2018) Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. Sci Rep 8:15629. https://doi.org/10.1038/s41598-018-34111-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Visram A, Chan KK, McGee P et al (2015) Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS One 10:e0120749. https://doi.org/10.1371/journal.pone.0120749

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramsey SD, Unger JM, Baker LH et al (2019) Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol 5:497–505. https://doi.org/10.1001/jamaoncol.2018.6437

Article  PubMed  PubMed Central  Google Scholar 

Hwang JP, Fisch MJ, Zhang H et al (2012) Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract 8:e32-39. https://doi.org/10.1200/JOP.2011.000450

Article  PubMed  PubMed Central  Google Scholar 

Hwang JP, Fisch MJ, Lok AS et al (2013) Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 13:534. https://doi.org/10.1186/1471-2407-13-534

Article  PubMed  PubMed Central  Google Scholar 

Voican CS, Mir O, Loulergue P et al (2016) Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 27:2172–2184. https://doi.org/10.1093/annonc/mdw414

Article  CAS  PubMed  Google Scholar 

Rossy Cancer Network: hepatitis B screening before treatment with rituximab (2018) https://www.mcgill.ca/rcr-rcn/scorecard/quality-dimension/safety/s1-hepatitis-b-screening-treatment-rituximab.

Reddy KR, Beavers KL, Hammond SP et al (2015) American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:215–219. https://doi.org/10.1053/j.gastro.2014.10.039

Article  CAS  PubMed  Google Scholar 

Paul S, Saxena A, Terrin N et al (2016) Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med 164:30–40. https://doi.org/10.7326/M15-1121

Article  PubMed  Google Scholar 

Lau GK, Yiu HH, Fong DY et al (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742–1749. https://doi.org/10.1053/j.gastro.2003.09.026

Article  CAS  PubMed  Google Scholar 

Jang JW, Choi JY, Bae SH et al (2006) A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43:233–240. https://doi.org/10.1002/hep.21024

Article  CAS  PubMed  Google Scholar 

Hsu C, Hsiung CA, Su IJ et al (2008) A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology 47:844–853. https://doi.org/10.1002/hep.22106

Article  CAS  PubMed  Google Scholar 

Huang YH, Hsiao LT, Hong YC et al (2013) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31:2765–2772. https://doi.org/10.1200/JCO.2012.48.5938

Article  CAS  PubMed  Google Scholar 

Zhang MY, Zhu GQ, Shi KQ et al (2016) Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget 7:30642–30658. https://doi.org/10.18632/oncotarget.8907

Article  PubMed  PubMed Central  Google Scholar 

Yang C, Qin B, Yuan Z et al (2016) Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol 15:501–511

CAS  PubMed  Google Scholar 

Yu S, Luo H, Pan M et al (2016) Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 38:1035–1043. https://doi.org/10.1007/s11096-016-0358-6

Article  CAS  PubMed  Google Scholar 

Terrault NA, Lok ASF, McMahon BJ et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67:1560–1599. https://doi.org/10.1002/hep.29800

Article  PubMed  Google Scholar 

European Association for the Study of the Liver. Electronic address eee and European Association for the Study of the L uropean (2017) EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67:370–398. https://doi.org/10.1016/j.jhep.2017.03.021

Article  Google Scholar 

Weinbaum CM, Williams I, Mast EE et al (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57:1

PubMed  Google Scholar 

Leber K, Otten H, Brandjes DPM et al (2021) Clinical practice of hepatitis B screening in patients starting with chemotherapy: a survey among Dutch oncologists. Eur J Cancer Care (Engl) 30(e13495):2021. https://doi.org/10.1111/ecc.13495

Article  Google Scholar 

Leber K, Otten J, Depla A et al (2019) Introduction of routine hepatitis B screening for all patients receiving cancer treatment. Neth J Med 77:19–24

CAS  PubMed  Google Scholar 

Zurawska U, Hicks LK, Woo G et al (2012) Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 30:3167–3173. https://doi.org/10.1200/JCO.2011.40.7510

Article  PubMed  Google Scholar 

Day FL, Karnon J, Rischin D (2011) Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29:3270–3277. https://doi.org/10.1200/JCO.2011.35.1635

Article  PubMed  Google Scholar 

Hicks LK, Leung P, Cape J (2013) Screening for hepatitis B virus prior to chemotherapy: a quality improvement project. J Clin Oncol 31:158–158. https://doi.org/10.1200/jco.2013.31.31_suppl.158

Article  Google Scholar 

Sammons MK, Patel D, Sepkowitz K et al (2013) Successful implementation of a universal screening program to prevent hepatitis B reactivation in a large cancer center: 848. Hepatology 58:609A-610A

Google Scholar 

Centers for Disease Control: Yellow Book, (2020) https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/hepatitis-b.

Visram A, Feld JJ (2015) Defining and grading HBV reactivation. Clin Liver Dis (Hoboken) 5:35–38. https://doi.org/10.1002/cld.426